(Q35016714)

English

Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study

scientific article published in January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

0 references

author name string

Maria Teresa Rosignoli

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Giorgio Di Loreto

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Paolo Dionisio

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

5-14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Tolerance to the repolarization effects of rac-sotalol during long-term treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and Tolerability of Prulifloxacin after Single Oral Administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety concerns with fluoroquinolones

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of three fluoroquinolones on QT analysis after standard treatment courses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac repolarization and the safety of new drugs defined by electrocardiography

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug-induced prolongation of the QT interval: why the regulatory concern?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/19995094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11319400-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35016714&oldid=1566757654"